Tianjin Institute of Pharmaceutical Research Co., Ltd.

Yuquan Li

Lida Tang

Weiren Xu

Wei Liu

Guilong Zhao

Meixiang Zou

Yuqiang Liu

Yafei Xie

Huihui Chen

Jingwei Wu

Haizhi Zhang

Xuyuan Liu

Changying Liu

Qian Shang

Lei Liu

Yuli Wang

Wei Wei

Bingni Liu

Shijun Zhang

Yingmei Han

Guangping Xia

Naxia Zhao

Changjiang Huang

Jing Jin

Zhixing Zhou

Xiaohua Kong

Chuan Li

Lingjun Li

Jing Yuan

Hui Yan

Songhui Wang

Xuemin Zheng

Qunchao Wei

Weiling Kong

Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: wherein the definitions of X, X, X, X, X, X, X, X, X, X, X, X, X, Xand Xare consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.

Glucagon-derived peptide and use thereof

The present invention provides a compound having a structure of formula (I), a preparation method and use thereof, and a pharmaceutical composition containing the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The present invention also provides a crystalline form of the compound, a preparation method and use of the crystalline form, and a pharmaceutical composition comprising the crystalline form. The compounds having the structure of formula (I) of the present invention are present in a solid form, which not only can solve the problem of clopidogrel resistance, but also can solve the problem of severe hemorrhagic side effect and poor safety of some drugs, as well as the problem of poor stability of existing compounds. It can be developed into an ADP receptor antagonist antiplatelet agent with clear therapeutic effect, no resistance and better stability. 

Thienopyridine derivatives containing unsaturated aliphatic olefinic bond, preparation method and use thereof

The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.

Crystal form of urate transporter 1 inhibitor and preparation method and use thereof

Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization. 

Method for preparing urate transporter 1 inhibitor

The present invention relates to the pharmaceutical field for the treatment of hyperuricemia and gout. In particular, the present invention relates to a carboxylic acid urate transporter 1 (URAT1) inhibitor of a general formula (I) containing a diarylmethane structure and a preparation method thereof, and a pharmaceutical composition containing the same and a use thereof in the preparation of medicaments for treating hyperuricemia and gout, 

Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof

Growing community of inventors

Tianjin, China

Yuquan Li